Jefferies Initiates Coverage On Baker Hughes with Buy Rating, Announces Price Target of $35
Jefferies analyst Lloyd Byrne initiates coverage on Baker Hughes (NASDAQ:BKR) with a Buy rating and announces Price Target of $35.
Jefferies Initiates Coverage On Hess with Hold Rating, Announces Price Target of $140
Jefferies analyst Lloyd Byrne initiates coverage on Hess (NYSE:HES) with a Hold rating and announces Price Target of $140.
Jefferies Initiates Coverage On Northern Oil & Gas with Buy Rating, Announces Price Target of $37
Jefferies analyst Lloyd Byrne initiates coverage on Northern Oil & Gas (NYSE:NOG) with a Buy rating and announces Price Target of $37.
Barclays Initiates Coverage On Johnson & Johnson with Equal-Weight Rating, Announces Price Target of $175
Barclays analyst Matt Miksic initiates coverage on Johnson & Johnson (NYSE:JNJ) with a Equal-Weight rating and announces Price Target of $175.
EF Hutton Initiates Coverage On Bone Biologics with Buy Rating, Announces Price Target of $2.25
EF Hutton analyst Constantine Davides initiates coverage on Bone Biologics (NASDAQ:BBLG) with a Buy rating and announces Price Target of $2.25.
JMP Securities Initiates Coverage On Exelixis with Market Outperform Rating, Announces Price Target of $26
JMP Securities analyst Silvan Tuerkcan initiates coverage on Exelixis (NASDAQ:EXEL) with a Market Outperform rating and announces Price Target of $26.
Barclays Initiates Coverage On Intuitive Surgical with Overweight Rating, Announces Price Target of $235
Barclays analyst Matt Miksic initiates coverage on Intuitive Surgical (NASDAQ:ISRG) with a Overweight rating and announces Price Target of $235.
Barclays Initiates Coverage On Tandem Diabetes Care with Overweight Rating, Announces Price Target of $75
Barclays analyst Matt Miksic initiates coverage on Tandem Diabetes Care (NASDAQ:TNDM) with a Overweight rating and announces Price Target of $75.
Barclays Initiates Coverage On Boston Scientific with Overweight Rating, Announces Price Target of $49
Barclays analyst Matt Miksic initiates coverage on Boston Scientific (NYSE:BSX) with a Overweight rating and announces Price Target of $49.